Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Noxopharm Ltd. ( (AU:NOX) ) has provided an announcement.
Noxopharm Limited announced that all resolutions were passed at its Annual General Meeting, with significant support for the adoption of the Remuneration Report. The company’s Sofra technology platform, which targets inflammatory and autoimmune diseases, holds potential for significant market impact, given the projected growth in the autoimmune disease therapeutics and immuno-oncology markets.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company utilizes its proprietary Sofra and Chroma technology platforms to enhance mRNA medicines and develop drugs targeting inflammation, autoimmunity, and oncology.
Average Trading Volume: 109,444
Technical Sentiment Signal: Sell
Current Market Cap: A$26.3M
For an in-depth examination of NOX stock, go to TipRanks’ Overview page.